Bolus insulin calculators (BCs) became available in insulin pumps in 2002 and are being integrated into glucose meters and portable device applets for use with multiple daily injections. A retrospective analysis of continuous subcutaneous insulin infusion data from the Actual Pump Practices (APP) study is used in this article to generate formulas for more precise BC settings.
A well-designed BC determines accurate bolus doses for carbohydrate intake and for correcting elevated glucose levels. It should also provide the logic necessary to track residual bolus insulin and reduce bolus recommendations to minimize insulin stacking. To provide appropriate bolus doses, a BC requires accurate settings for the carbohydrate factor or insulin:carbohydrate ratio, glucose correction factor, duration of insulin action, and correction target. We provide guidelines to select BC settings from the user's current total daily dose (TDD) of insulin and to determine more appropriate BC settings from an improved TDD based on the mean glucose level.
WalshJRobertsRBaileyT. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol.2010; 4 (5): 1174–81.
2.
Del SindacoPCiofettaMLalliCPerrielloGPampanelliSTorloneEBrunettiPBolliGB. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med.1998; 15 (7): 592–600.
GargSKRosenstockJWaysK. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract.2005; 11 (1): 11–7.
5.
WalshJWroblewskiDBaileyTS. Disparate bolus on board recommendations in insulin pump therapy. AACE meeting. 2007: Poster.
6.
MudaliarSRLindbergFAJoyceMBeerdsenPStrangePLinAHenryRR. Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care.1999; 22 (9): 1501–6.
7.
HeiseTWeyerCSerwasAHeinrichsSOsingaJRoachPWoodworthJGudatUHeinemannL. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care.1998; 21 (5): 800–3.
8.
RaveKNosekLde la PeñaASegerMErnestCS2ndHeinemannLBatyckyRPMuchmoreDB. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care.2005; 28 (10): 2400–5.
9.
HeinemannL. Time-action profiles of insulin preparations. Mainz, Germany: Kirchheim & Co GmbH; 2004.
10.
HeinemannLWeyerCRauhausMHeinrichsSHeiseT. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care.1998; 21 (11): 1910–4.
11.
Pedersen-BjergaardUPrammingSHellerSRWallaceTMRasmussenAKJørgensenHVMatthewsDRHougaardPThorsteinssonB. Severe hypoglycaemia in 1076 patients with type 1 diabetes: Influence of risk markers and selection. Diabetes Metab Res Rev.2004; 20 (6): 479–86.
12.
DonnellyLAMorrisADFrierBMEllisJDDonnanPTDurrantRBandMMReekieGLeeseGP; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: A population-based study. Diabet Med.2005; 22 (6): 749–55.
13.
NathanDMKuenenJBorgRZhengHSchoenfeldDHeineRJ; A1c-Derived Average Glucose Study Group. Translating the hemoglobin A1C assay into estimated average glucose values. Diabetes Care.2008; 31 (8): 1473–8.
14.
HolterhusPOdendahlROesingmannSLeplerRWagnerVHiortOHollR; German/Austrian DPV Initiative; German Pediatric CSII Working Group. Classifcation of distinct baseline insulin infusion patterns in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion therapy. Diabetes Care.2007; 30 (3): 568–73.
15.
ScheinerGBoyerBA. Characteristics of basal insulin requirements by age and gender in type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract.2005; 69 (1): 14–21.
16.
WalshJRobertsRVarmaCBaileyT. Using insulin. San Diego: Torrey Pines Press; 2003.
DavidsonPCHebblewhiteHRSteedRDBodeBW. Analysis of guidelines for basal-bolus dosing: Basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract.2008; 14 (9): 1095–101.
20.
KingAArmstrongD. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: Basal dosing. J Diabetes Sci Technol.2007; 1 (1): 36–41.
21.
KingA. How much insulin do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoring. Endocr Pract.2010; 16 (3): 428–32.
22.
WalshJRobertsR. Letter to the editor. A study that glucose control can be achieved in 31 type 1 patients who follow a controlled diet and use an insulin pump that is programmed. J Diabetes Sci Technol.2007; 1 (4): L3–6.
